OverviewSuggest Edit

Evotec is a drug discovery alliance and development partnership company. It provides pharmaceutical and biotechnology companies, academics, patient advocacy groups, and venture capital firms with drug discovery solutions in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of innovative drug candidates, and consulting arrangements. The company specializes in the areas of neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, and fibrosis.

TypePublic
Founded1993
HQHamburg, DE
Websiteevotec.com
Employee Ratings3.1

Latest Updates

Employees (est.) (Jun 2019)2,756(+22%)
Share Price (May 2020)€24.3 (+2%)

Key People/Management at Evotec

Werner Lanthaler

Werner Lanthaler

Chief Executive Officer
Cord Dohrmann

Cord Dohrmann

Chief Scientific Officer
Enno Spillner

Enno Spillner

Chief Financial Officer
Gabriele Hansen

Gabriele Hansen

SVP, Corporate Communications, Marketing & Investor Relations
Show more

Evotec Office Locations

Evotec has offices in Hamburg, Göttingen, Köln, Planegg and in 8 other locations
Hamburg, DE (HQ)
Essener Bogen 7
Göttingen, DE
Marie-Curie-Straße 7
Köln, DE
Nattermannallee 1/S20
Planegg, DE
19A Am Klopferspitz
Orth an der Donau, AT
Uferstraße 15
Lyon, FR
40 Avenue Tony Garnier
Show all (12)

Evotec Financials and Metrics

Evotec Revenue

Market capitalization (29-May-2020)

3.7b

Closing stock price (29-May-2020)

24.3
Evotec's current market capitalization is €3.7 b.
Show all financial metrics

Evotec Acquisitions / Subsidiaries

Company NameDateDeal Size
AptuitJuly 30, 2017$300 m

Evotec Online and Social Media Presence

Embed Graph

Evotec News and Updates

Evotec expands its iPSC-based cell therapy platform EVOcells through licensing agreement with panCELLa

EVOTEC LICENSES PANCELLA’S STATE-OF-THE-ART IPSC TECHNOLOGIES IACT STEALTH CELL™ AND FAILSAFE™ FOR USE IN CELL THERAPY ACCESS TO PANCELLA’S TECHNOLOGY HAS THE POTENTIAL TO ENABLE SAFE AND OFF-THE-SHELF CELL THERAPY PRODUCTS AND LIFTS EVOTEC’S IPSC-BASED CELL THERAPY PLATFORM (“EVOcells”) TO THE NEXT…

Evotec and Ildong to collaborate with development projects on INDiGO platform

EVOTEC LEVERAGES INDIGO PLATFORM TO ACCELERATE DEVELOPMENT OF VARIOUS ILDONG PROGRAMMES INTO THE CLINIC FIRST REGULATORY FILING ENVISAGED FOR Q1 2021 INDIGO IS A KEY VALUE-DRIVING COMPONENT OF EVOTEC’S EVT EXECUTE BUSINESS SEGMENT AIMED AT REDUCING TIME FROM NOMINATION TO REGULATORY SUBMISSION.read …

Evotec and Indivumed Announce Second Joint Drug Discovery Program

HAMBURG, Germany, Jan. 23, 2020 /PRNewswire/ -- Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) and Indivumed GmbH ("Indivumed") today announced that the companies have entered into a new research collaboration to discover and develop first-in-class therapeutics...

Just Evotec Biologics enters into multi-year collaboration with MSD around facility of the future

MSD TO GAIN ACCESS TO MANUFACTURING KNOW-HOW WITHIN JUST – EVOTEC BIOLOGICS’ J.POD® FACILITY (“FACILITY OF THE FUTURE”) MULTI-YEAR COLLABORATION IN FORM OF CAPACITY RESERVES FOR PRODUCTION OF MSD BIOLOGICS read more

Evotec expands service agreement with Sanofi to create a centralised global sample management hub in Toulouse

CENTRALISATION OF SAMPLE COMPOUNDS IN TOULOUSE PROVIDES GREATER EFFICIENCY FOR SANOFI’S SMALL MOLECULE DRUG DISCOVERY EFFORTS LATEST DISPENSING TECHNOLOGY WILL HELP OPTIMISE COMPOUND ACCESS ACROSS GLOBAL RESEARCH SITES.read more

Evotec and Vifor Pharma form joint venture for early development in nephrology

VIFOR PHARMA AND EVOTEC TO CREATE A JOINTLY-OWNED DRUG DISCOVERY AND DEVELOPMENT PLATFORM FOR INNOVATIVE NEPHROLOGY THERAPEUTICS COLLABORATION BRINGS TOGETHER EVOTEC’S BEST-IN-CLASS DRUG DISCOVERY CAPABILITIES AND VIFOR PHARMA’S DEVELOPMENT AND COMMERCIALISATION EXPERTISE IN NEPHROLOGY JOINT VENTURE…
Show more

Evotec Frequently Asked Questions

  • When was Evotec founded?

    Evotec was founded in 1993.

  • Who are Evotec key executives?

    Evotec's key executives are Werner Lanthaler, Cord Dohrmann and Enno Spillner.

  • How many employees does Evotec have?

    Evotec has 2,756 employees.

  • Who are Evotec competitors?

    Competitors of Evotec include Inovio Pharmaceuticals, Regenxbio and Sangamo BioSciences.

  • Where is Evotec headquarters?

    Evotec headquarters is located at Essener Bogen 7, Hamburg.

  • Where are Evotec offices?

    Evotec has offices in Hamburg, Göttingen, Köln, Planegg and in 8 other locations.

  • How many offices does Evotec have?

    Evotec has 12 offices.